

12 5-HT3 antagonists (ondansetron) versus placebo

Figure 136: Fatigue: Checklist Individual Strength fatigue at 12 weeks




Figure 137: Activity levels: Actometer (objective accelerometer-based method of measuring activity) at 12 weeks




Figure 138: Adverse events: constipation




Figure 139: Adverse events: malaise




Figure 140: Symptom scales: Sickness Impact Profile (SIP) 8 at 12 weeks

